Lasa Supergenerics collaborates with ICT for development of antiviral compound Favipiravir as Covid19 Treatment

Lasa Supergenerics in collaboration with Institute of Chemical Technology (ICT) recently announced commencement for Development of antiviral Compound Favipiravir as Covid19 Treatment.

Favipiravir is an antiviral drug and is a promising antidote for the treatment of Coronavirus disease (COVID-2019). It possesses activity against many RNA viruses. It is a guanine analogue approved for influenza treatment. It can effectively inhibit the RNA-dependent RNA polymerase of RNA viruses such as influenza, Ebola, yellow fever, chikungunya, norovirus and enterovirus, and a recent study reported its activity against 2019-nCoV.

Powered by Capital Market - Live News